Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.47 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
| ▸ | PRKCB | P05771 | 2/20 | 0.42 |
| ▸ | PRKCA | P17252 | 2/20 | 0.42 |
| ▸ | PRKCH | P24723 | 2/20 | 0.42 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.42 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.42 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | CASP1 | P29466 | 3/20 | 0.40 |
| ▸ | CASP4 | P49662 | 1/20 | 0.40 |
| ▸ | CASP5 | P51878 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5788761 | 0.94 | HIF1A (0.53) | KDM4ELMNAHIF1AS1PR2KMT2A | |
| SCHEMBL5786466 | 0.91 | ALDH1A1 (0.60) | KDM4ELMNAHIF1AS1PR2KMT2A | |
| SCHEMBL5786281 | 0.88 | ALDH1A1 (0.49) | KDM4ELMNAHIF1AS1PR2KMT2A | |
| SCHEMBL5784894 | 0.86 | PRKCB (0.53) | KDM4EKMT2ANPSR1ALDH1A1SCN9A | |
| SCHEMBL5788559 | 0.86 | ALDH1A1 (0.47) | KDM4ELMNAHIF1AS1PR2KMT2A | |
| SCHEMBL5788424 | 0.83 | ALDH1A1 (0.47) | KDM4ELMNAHIF1AS1PR2KMT2A | |
| SCHEMBL5787458 | 0.83 | ALDH1A1 (0.53) | KDM4ELMNAHIF1AS1PR2KMT2A | |
| SCHEMBL5789371 | 0.83 | KDM4E (0.51) | KDM4ELMNAHIF1AS1PR2KMT2A | |
| SCHEMBL5787181 | 0.81 | ALDH1A1 (0.48) | KDM4ELMNAHIF1AS1PR2KMT2A | |
| SCHEMBL5787010 | 0.81 | ALDH1A1 (0.52) | KDM4ELMNAHIF1AS1PR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1685115-A1 | NOVEL NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Warner-Lambert Company LLC (US) | 2006-08-02 | — | — | EP | claimed |
| WO-2005042501-A1 | NOVEL NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT COMPANY LLC (US) | 2005-05-12 | — | — | WO | claimed |
| US-20050096327-A1 | Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders | WARNER-LAMBERT COMPANY LLC | 2005-05-05 | — | — | US | claimed |
| EP-1685115-A1 | NOVEL NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Warner-Lambert Company LLC (US) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005042501-A1 | NOVEL NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT COMPANY LLC (US) | 2005-05-12 | — | — | WO | disclosed |
| US-20050096327-A1 | Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders | WARNER-LAMBERT COMPANY LLC | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096327-A1 | Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders | SLC6A2, SLC18A2, SLC6A3 | KDM4E 1392/4885LMNA 3234/4885HIF1A 2928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.